Novo Nordisk's Answer to Retatrutide is Even Better: UBT251

New study on UBT251, which seems a little better for weight loss than reta, at 24 weeks out:

www.biopharmadive.com

Novo, searching for a spark, spotlights new data for three-pronged obesity drug

Novo’s answer to a closely watched Lilly drug spurred roughly 20% weight loss after 24 weeks in a Phase 2 trial, results one of its executives claimed to be “differentiating.”
www.biopharmadive.com www.biopharmadive.com

  • An experimental, triple-acting obesity drug from Novo Nordisk helped some patients in a Phase 2 trial in China lose up to a fifth of their body weight, the company said Tuesday.

  • The study, run by Novo’s Guangdong, China-based development partner United Biotechnology, enrolled 205 patients who are overweight or have obesity and tested three different doses of the therapy, UBT251, against a placebo over 24 weeks. According to Novo, the highest average weight loss observed over that time was 19.7%, versus 2% for placebo recipients.

  • Novo didn’t provide other details, but said all dose groups had statistically significant improvements compared to a placebo on key secondary measures of metabolic health. The most common side effects were gastrointestinal in nature and the “vast majority” were mild to moderate and diminished over time, the company said. Initial data from a global Phase 1b/2a study are expected next year...

    In a mid-stage study published in The New England Journal of Medicine three years ago, retatrutide treatment led to as much as 17.5% weight loss after 24 weeks. Without mentioning retatrutide by name, Martin Holst Lange, Novo’s chief scientific officer and research head, claimed in a statement Tuesday that UBT251’s results suggest a “differentiated” clinical, safety and tolerability profile.
Click to expand...
 
Last edited:
I get nervous about how desperate it seems they're getting to have that 0.001% edge over each other. I'm glad tirz is working for me, because everything I know about corporations under pressure to make a billion dollars whispers that somebody's gonna push SOMETHING through that hurts people eventually. It's not tirz, and I doubt it's reta, but I believe it'll be SOMETHING, and it's so important to me not to be holding the early-adopter bag when that happens.
 
Better is a relative concept. Is losing more weight in a shorter amount of time always good? Gall and kidney stones are a possibility when losing large amounts of weight quickly. Also, if they achieved this by cranking up the glucagon agonist component, it could mean more thermogenesis and fat burning, but also potentially more tolerability issues. They haven't released the weights of GLP1/GIP and glucagon yet and Phase I readouts aren't scheduled until next year, but it will be interesting. They seem to be racing to find out what the limits of human metabolic weight loss really are.
 
Last edited:
The more new drugs the better. I think a lot of the drugs that have been in development that are injectable and not triple agonists will end up being dropped, as they won't compete with reta or any of the other ones being worked out. But over the longer term the more drugs the more competition and eventually saner pricing. The holy grail would be an oral triple agonist but I have not heard of one yet.
This one sounds very good, and unless something goes wrong, will keep going. You really need to know the incidence of side effects vs weight loss to compare drugs, as otherwise just giving a bit higher dose is going to make that drug look more effective, even if it causes more nausea or vomiting .
 
lessthanhalf said:
The more new drugs the better. I think a lot of the drugs that have been in development that are injectable and not triple agonists will end up being dropped, as they won't compete with reta or any of the other ones being worked out. But over the longer term the more drugs the more competition and eventually saner pricing. The holy grail would be an oral triple agonist but I have not heard of one yet.
This one sounds very good, and unless something goes wrong, will keep going. You really need to know the incidence of side effects vs weight loss to compare drugs, as otherwise just giving a bit higher dose is going to make that drug look more effective, even if it causes more nausea or vomiting .
Click to expand...
Yeah, saner prices in AUS maybe. The best one gets the golden ring in the USA.
 
Meh, high-dose mazdutide already largely matches retatrutide performance at 12 weeks. In fact, it's doing that in lower BMI people (believe mazdutide was an average starting BMI of ~32 and retatrutide was a starting BMI of ~37), making it all the more impressive. At 12 weeks the results are more about dosage and dose escalation rate for each.

I'm all for more good options in the space, but average weight loss numbers at the end of the trial will be what gets reported in the headlines.
 
And what even is that chart representing? The Y-axis appears to be in negative percent, but that's can't possibly be correct. Obviously none of these drugs are achieving the numbers plotted at the 12 week mark.
 
fatbegone said:
Couldn't find a graph in English. Apologies. Here's an article on UBT251 -> https://www.fiercebiotech.com/biote...triple-g-agonist-tied-15-weight-loss-12-weeks
View attachment 6479
Click to expand...
If we are whipping out who has the biggest weight loss drugs Why settle for nn-9559 or UBT-251 when you can look forward to NA-931

What NA-931 TargetsIt's a first-in-class, oral small-molecule quadruple agonist that simultaneously activates:
  • GLP-1 (appetite suppression, glucose control)
  • GIP (insulin sensitivity, fat metabolism)
  • Glucagon (energy expenditure, fat burning)
  • IGF-1 (insulin-like growth factor-1, which supports muscle growth, repair, and lean mass preservation)
The key differentiator here is the IGF-1 component—IGF-1 pathways help counteract the catabolic (muscle-breaking) effects common with GLP-1-based drugs, where 15–40% of weight loss can come from lean mass (especially concerning at age 52+ for sarcopenia risk).
 

Attachments

  • alakablam.webp
    alakablam.webp
    52.3 KB · Views: 9
lessthanhalf said:
Sadly it is not a peptide and as far as I know the chemical structure is not published so no pirate Chinese versions in the near future.
Click to expand...
I got to hand it to the Chinese, One things is they do have plenty of willing volunteers (Uyghurs) to preform these trials on the population.
 
DjJoshua said:
If we are whipping out who has the biggest weight loss drugs Why settle for nn-9559 or UBT-251 when you can look forward to NA-931

What NA-931 TargetsIt's a first-in-class, oral small-molecule quadruple agonist that simultaneously activates:
  • GLP-1 (appetite suppression, glucose control)
  • GIP (insulin sensitivity, fat metabolism)
  • Glucagon (energy expenditure, fat burning)
  • IGF-1 (insulin-like growth factor-1, which supports muscle growth, repair, and lean mass preservation)
The key differentiator here is the IGF-1 component—IGF-1 pathways help counteract the catabolic (muscle-breaking) effects common with GLP-1-based drugs, where 15–40% of weight loss can come from lean mass (especially concerning at age 52+ for sarcopenia risk).
Click to expand...
Big pharma finally catching up to bro science.
 
Calm Logic said:
Big pharma finally catching up to bro science.
Click to expand...
How about a 100% non glp1..... look at this.. The Allurion Gastric Balloon (also known as the Allurion Balloon or previously the Elipse Balloon in earlier studies). It's a swallowable intragastric balloon designed for non-surgical weight loss.
 

Attachments

  • alakablam.webp
    alakablam.webp
    52.3 KB · Views: 4
swimmer said:
I check all 4 boxes with my ghetto NA-931.
Tirz, Maz, IGF1-lr3

(although it would be nice to only pin once a week)
Click to expand...
NA-931 is a daily, small molecule oral pill, as with orfo. But NA-931 will take a while to be released, like 2028.

NA-931

NA-931 is for the treatment Diabetes Obesity and Alcohol Use Disorder
www.biomedind.com
NA-931 has an estimated half-life of 16–24 hours, supporting its once-daily oral administration.
Click to expand...
 
Last edited:
Of interest the new study of reta from Lilly states that 12-18% drop out rate because people thought that they were loosing to much weight. Will be interesting to see the clinical data on NA-931
 
Calm Logic said:
NA-931 is a daily, small molecule oral pill, as with orfo. But NA-931 will take a while to be released, like 2028.

NA-931

NA-931 is for the treatment Diabetes Obesity and Alcohol Use Disorder
www.biomedind.com
Click to expand...
This is vaporware

https://ausaminos.com/blog/the-bioglutide-scam-lies-and-fraud-at-biomed-industries/

I would also ask myself why they're the only company with quadruple agonist oral GLP1 when the other more advanced companies have barely cracked the code on making an oral monoagonist.
 
what happened to the one that was supposed to build muscle? (not that gym bro type of stuff but it was glp1 category) I read about it a couple of years back
 
As far as I know the one with reasonable evidence in human trials is the SARM ostarine, at a much lower than body building dose of 3mg/day combined with semaglutide it caused weight loss with very little muscle loss and hardly any extra side effects. Pity there is only one small study in obesity and a few in cancer patients, but overall much better evidence base than most of the peptides. Would probably still need liver function test monitoring as I think at higher doses it has caused abnormalities there. As far as I know it is still in active development. It would be hard to use as the only way to buy it is 25mg pills , which is not going to be super easy to split into 3mg doses unless the pills are big and well mixed. But it would be ultracheap at $30-40 usd for 800 doses plus a few extra $ for some empty capsules. And it did not cause androgenic effects in female cancer patients. The weird thing about nearly all the studies of muscle building drugs is they often show bigger muscles and then fail to show improved strength or physical performance. There is a big market for something that works and is safe for obesity and for frail elderly people with weak muscles ( sarcopenia )
GLP therapies show the opposite, smaller muscles but improved muscle quality and performance, with significantly reduced intramuscular fat.
At least one of the myostatin inhibiting antibody therapies has been dropped, I think for business rather than pharmacology reasons.
It is not really possible to know if na-931 is legit as they clearly don't want chinese peptide pirates copying it so hardly any information is being released. It was in the stiefel obesity report which is basically a summary of the field for investors , and they thought it was ok 7 or 8 months ago.
 
Is the GIP KI lower on this one or will it still bump the hr to 100 ?

Why settle for this when you can inject cafraglutide once a month ?
 
There haven’t been any headlines I can find on NA-931 for the past few months. Despite Phase II clinical trials, it’s still widely reported that this compound (NA-931 or bioglutide) is actually a hoax and does not exist.

1772107597629.webp
 
ok I think the muscle building one I read about was pemvidutide, it mimics exercise.

another one called Trevogrumab. There's currently a US clinical trial called Regeneron's COURAGE trial with semaglutide if anyone is interested in getting paid to take glp1s.
 
latviantower said:
There haven’t been any headlines I can find on NA-931 for the past few months. Despite Phase II clinical trials, it’s still widely reported that this compound (NA-931 or bioglutide) is actually a hoax and does not exist.

View attachment 16555
Click to expand...
The genius touting it was outed as a fraud. It was always a fraud.
 
You must log in or register to reply here.

Trending Topics

Latest Posts

Forum Statistics

Threads
18,477
Posts
192,266
Members
61,775
Newest
Intriguedat60
Back
Top Bottom